Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before. Analysts have questioned whether Novo can remain a leader in the highly competitive market ...

Novo hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales, saying it now expects adjusted sales and profit to contract between 4% and 12%. Novo said ...

Novo nudges up full-year guidance after sales, profit beats Obesity market is expanding despite price pressure - investors Novo to launch its pill outside U.S. this year Novo trying to reel in rival ...

Novo Nordisk (NVO) is set to report Q1 earnings on Wednesday, May 6, before market open, with investors closely watching whether the company can reassert leadership in the increasingly competitive ...

LONDON/COPENHAGEN, May 7 (Reuters) - Early data from weight-loss pills are lifting shares in Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab as investors bet that easier-to ...

Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the pharma ending hopes of delivering the therapy in a single-chamber device.

The stock has sold off for a good reason, and I covered it in my previous article on NVO. But I find the repricing that Novo has gone through to be too brutal to sustain, especially given the changing ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The semaglutide franchise is changing up its branding as Novo Nordisk, seeing the cultural phenomenon that has become Ozempic, is retiring the Rybelsus name in favor of its better-known brand. Meet ...